

HR 1840

Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Taxation

Introduced: Mar 30, 2017

Current Status: Referred to the House Committee on Ways and Means.

Latest Action: Referred to the House Committee on Ways and Means. (Mar 30, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/1840>

Sponsor

Name: Rep. Paulsen, Erik [R-MN-3]

Party: Republican • **State:** MN • **Chamber:** House

Cosponsors (9 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Green, Gene [D-TX-29]	D · TX		Mar 30, 2017
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Mar 30, 2017
Rep. Shimkus, John [R-IL-15]	R · IL		Mar 30, 2017
Rep. Thompson, Mike [D-CA-5]	D · CA		Mar 30, 2017
Rep. Walz, Timothy J. [D-MN-1]	D · MN		Mar 30, 2017
Rep. Eshoo, Anna G. [D-CA-18]	D · CA		May 23, 2017
Rep. Engel, Eliot L. [D-NY-16]	D · NY		Jun 7, 2017
Rep. DesJarlais, Scott [R-TN-4]	R · TN		Jul 14, 2017
Rep. Lance, Leonard [R-NJ-7]	R · NJ		Sep 5, 2017

Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred To	Mar 30, 2017

Subjects & Policy Tags

Policy Area:

Taxation

Related Bills

No related bills are listed.

Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017

This bill amends the Internal Revenue Code to allow tax credits for 50% of the clinical testing expenses for: (1) infectious disease products that are intended to treat a serious or life-threatening infection, including one caused by an antibacterial or antifungal resistant pathogen or a qualifying pathogen listed by the Department of Health and Human Services as having the potential to pose a serious threat to public health; and (2) in-vitro diagnostic devices that identify in less than four hours the presence, concentration, or characteristics of a serious or life-threatening infection.

Actions Timeline

- **Mar 30, 2017:** Introduced in House
- **Mar 30, 2017:** Referred to the House Committee on Ways and Means.